Abstract 4169: Decreased Serum Ghrelin Level in Patients with Acute Myocardial Infarction: Its Association with the Infarct Size and Left Ventricular Dysfunction
Background: Ghrelin, a circulating brain-gut peptide, has been identified as potent ligand for the growth-hormone secretagogues receptor, distributed in cardiovascular system. Experimental studies demonstrated that ghrelin has protective effects against ischemia-reperfusion injury and apoptosis. Therefore, the present study was designed to investigate the role of ghrelin in patients with acute myocardial infarction (AMI).
Methods: Forty-six patients were studied and divided into the following four groups; 16 patients with AMI (M/F=15/1, 67±10[mean±SD]years, body mass index (BMI, kg/m2; 23±2), 12 patients with unstable angina pectoris (uAP: M/F=9/3, 64±5years, BMI;23±2), 13 patients with stable AP (sAP: M/F=12/1, 66±6years, BMI;22±2) and 5 control patients with chest pain without any coronary artery disease (M/F=4/1, 66±5years, BMI; 23±2). Serum ghrelin level was measured by newly developed enzyme immunoassay system (MM-402, Mitsubishi Kagaku Medical Inc.). The sensitivity of this system is 2.5fmol/mL.
Results: In comparison with control, sAP and uAP patients, serum ghrelin levels were significantly decreased on day 0 (on admission) in AMI patients. In next two weeks, ghrelin levels recovered with a time-dependent trend (P<0.01). In patients with AMI, serum level on day 14 divided by that on day 0, an index of MI-related acute change in ghrelin, correlated positively with peak creatinine phosphokinase level (R=0.74, P<0.01) and negatively with left ventricular ejection fraction (R=-0.53, P<0.05).
Conclusions: In patients with AMI, secretion of ghrelin is suppressed in association with a large infarct size and left ventricular dysfunction. Considering cardioprotective effect of ghrelin, its exogenous administration will provide new perspective for AMI treatment.